Detalles de la búsqueda
1.
A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor.
Br J Clin Pharmacol;
88(5): 2140-2155, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34773923
2.
Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.
Pharm Res;
37(12): 233, 2020 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-33123802
3.
Impact of physiologically based pharmacokinetic modeling and simulation in drug development.
Drug Metab Dispos;
41(12): 1994-2003, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24009310
4.
Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.
Br J Clin Pharmacol;
75(2): 488-96, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22670830
5.
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Chem Res Toxicol;
25(10): 2067-82, 2012 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22931300
6.
Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk.
Drug Metab Dispos;
39(11): 2076-84, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21832001
7.
Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie".
Drug Metab Dispos;
37(11): 2255-61, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19679676
8.
Comparison of 2-aminophenol and 4-nitrophenol as in vitro probe substrates for the major human hepatic sulfotransferase, SULT1A1, demonstrates improved selectivity with 2-aminophenol.
Biochem Pharmacol;
74(2): 352-8, 2007 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17506995
9.
Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.
Eur J Pharm Biopharm;
117: 224-231, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28385615
10.
The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.
BMC Pharmacol Toxicol;
16: 18, 2015 Jun 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-26092545
11.
The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers.
Eur J Drug Metab Pharmacokinet;
39(3): 173-81, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24504700
12.
The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.
Bioorg Med Chem Lett;
13(6): 1067-70, 2003 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-12643913
13.
The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.
Bioorg Med Chem Lett;
12(18): 2603-6, 2002 Sep 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-12182870
Resultados
1 -
13
de 13
1
Próxima >
>>